A
Aclaris Therapeutics D
D
ACRS
2.14000
USD
-0.11
(-4.89%)
مغلق
حجم التداول
99,603
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
231,830,947
الأخبار المقالات
العنوان: Aclaris Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.